http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03028001-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbab1cdc8076ff0865196f53d59e8bbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66996dcf2dc59f595b8c0584986d50b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85d28e5b464da9e31f73500b0a4f0001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a00ac81649624b1ca7bdd69f6d4f2218
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bb76de8a47426a14001bbf25ee7016b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1fc5c4e8c8bfb71d79325ec48839454
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-453
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453
filingDate 2002-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bbc48dd8e79db1960bf6bf1a29f16a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a644d1cc482e2d482c393996ec7fc3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6587cd7402103f7319a122a72629865b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9baba0bde2405ad4b5ffdd04cdfa49b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1256fdde1d7df3e9c13a2626dbaba2a
publicationDate 2003-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-03028001-A3
titleOfInvention Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
abstract The present invention relates to a cancer cell- specific apoptosis inducing composition. The TNF (tumor necrosis factor; hereinafter, referred to as ' TNF ') family proteins and flavopiridol (also its salts) and the like are individually disadvantageous to provoke a serious side effect such as toxicity against an excessive dose, although they have excellent anti-cancer effects respectively. The composition of the present invention is prepared by combining the TNF family protein and flavopiridol, which reduces the toxicity or the side effect induced during the independent treatment at an high concentration, since the TNF family protein and flavopiridol are blended at an low concentration. Also, the composition has a specific action for cancer cells and a synergistic efficacy pharmaceutically.
priorityDate 2001-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395787
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395786
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID21926
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403922
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484888
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397086
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5287969
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494186
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID554167
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID744399
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID36054
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5459219
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID114461
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID24835
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7124
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100126739

Total number of triples: 42.